Avantor Inc. (NYSE:AVTR) is one of the most undervalued mid cap stocks to buy now. On February 12, Bank of America analyst Michael Ryskin lowered the firm’s price target on Avantor to $11 from $13 and kept a Neutral rating. This decision followed a sharp market reaction to a soft FY 2026 guidance.
The firm noted that visibility into a potential recovery remains limited as management has yet to provide a clear path to improvement, leading to expectations that the shares will remain under pressure. The revised price target reflects these lower growth and multiple assumptions.
On the same day, Citi lowered its price target on Avantor Inc. (NYSE:AVTR) to $11 from $13 and maintained a Neutral rating following the company’s Q4 2025 results and FY 2026 guidance, which came in below expectations. The firm particularly noted that investors may not view the guidance as conservative, especially given the required ramp-up from Q1 earnings-per-share, which was guided well below expectations at $0.15 to $0.16.
Avantor Inc. (NYSE:AVTR) provides mission-critical products and services to customers in the biopharma, healthcare, education & government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
While we acknowledge the potential of AVTR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
